1. Home
  2. ATNM vs IXHL Comparison

ATNM vs IXHL Comparison

Compare ATNM & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • IXHL
  • Stock Information
  • Founded
  • ATNM 2000
  • IXHL 2001
  • Country
  • ATNM United States
  • IXHL Australia
  • Employees
  • ATNM N/A
  • IXHL N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • IXHL
  • Sector
  • ATNM Health Care
  • IXHL
  • Exchange
  • ATNM Nasdaq
  • IXHL Nasdaq
  • Market Cap
  • ATNM 50.2M
  • IXHL 54.5M
  • IPO Year
  • ATNM N/A
  • IXHL N/A
  • Fundamental
  • Price
  • ATNM $1.61
  • IXHL $0.53
  • Analyst Decision
  • ATNM Strong Buy
  • IXHL
  • Analyst Count
  • ATNM 2
  • IXHL 0
  • Target Price
  • ATNM $4.50
  • IXHL N/A
  • AVG Volume (30 Days)
  • ATNM 122.2K
  • IXHL 114.5M
  • Earning Date
  • ATNM 11-13-2025
  • IXHL 11-13-2025
  • Dividend Yield
  • ATNM N/A
  • IXHL N/A
  • EPS Growth
  • ATNM N/A
  • IXHL N/A
  • EPS
  • ATNM N/A
  • IXHL N/A
  • Revenue
  • ATNM N/A
  • IXHL $98,000.00
  • Revenue This Year
  • ATNM N/A
  • IXHL $2,538.49
  • Revenue Next Year
  • ATNM N/A
  • IXHL $249.95
  • P/E Ratio
  • ATNM N/A
  • IXHL N/A
  • Revenue Growth
  • ATNM N/A
  • IXHL N/A
  • 52 Week Low
  • ATNM $1.03
  • IXHL $0.08
  • 52 Week High
  • ATNM $2.41
  • IXHL $3.12
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 45.72
  • IXHL 48.05
  • Support Level
  • ATNM $1.60
  • IXHL $0.51
  • Resistance Level
  • ATNM $1.70
  • IXHL $0.59
  • Average True Range (ATR)
  • ATNM 0.07
  • IXHL 0.05
  • MACD
  • ATNM -0.01
  • IXHL -0.01
  • Stochastic Oscillator
  • ATNM 32.14
  • IXHL 12.99

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: